Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review Article
  • Published:

ERBB3 mutations in cancer: biological aspects, prevalence and therapeutics

Oncogene volume 39, pages 487–502 (2020)Cite this article

Subjects

Abstract

HER3, a member of the EGFR family of receptor tyrosine kinases coded by the ERBB3 gene, plays an important role in cancer, despite its lack of intrinsic kinase activity. As with genes coding for potential heterodimeric partners of HER3, EGFR, and HER2, oncogenic mutations of ERBB3 have been explored by several studies. In this review, we discuss the evidence presenting ERBB3 somatic mutations as potential tumoral drivers. We then show that ERBB3 mutations are not uncommon in many cancer types. Finally, we present the recent results of several studies evaluating different therapeutic approaches for treating patients with oncogenic ERBB3 mutations.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Hauschild A, Grob J-J, Demidov LV, Jouary T, Gutzmer R, Millward M, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012;380:358–65.

    Article  CAS  PubMed  Google Scholar 

  2. DeMatteo RP, Ballman KV, Antonescu CR, Maki RG, Pisters PW, Demetri GD, et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet. 2009;373:1097–104.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350:2129–39.

    Article  CAS  PubMed  Google Scholar 

  4. Sithanandam G, Anderson LM. The ERBB3 receptor in cancer and cancer gene therapy. Cancer Gene Ther. 2008;15:413–48.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Kraus MH, Issing W, Miki T, Popescu NC, Aaronson SA. Isolation and characterization of ERBB3, a third member of the ERBB/epidermal growth factor receptor family: evidence for overexpression in a subset of human mammary tumors. Proc Natl Acad Sci USA. 1989;86:9193–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Burgess AW, Cho H-S, Eigenbrot C, Ferguson KM, Garrett TPJ, Leahy DJ, et al. An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. Mol Cell. 2003;12:541–52.

    Article  CAS  PubMed  Google Scholar 

  7. Shi F, Telesco SE, Liu Y, Radhakrishnan R, Lemmon MA. ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation. Proc Natl Acad Sci USA. 2010;107:7692–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Collier TS, Diraviyam K, Monsey J, Shen W, Sept D, Bose R. Carboxyl group footprinting mass spectrometry and molecular dynamics identify key interactions in the HER2-HER3 receptor tyrosine kinase interface. J Biol Chem. 2013;288:25254–64.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Littlefield P, Liu L, Mysore V, Shan Y, Shaw DE, Jura N. Structural analysis of the EGFR/HER3 heterodimer reveals the molecular basis for activating HER3 mutations. Sci Signal. 2014;7:ra114–ra114.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  10. Cho H-S. Structure of the extracellular region of HER3 reveals an interdomain tether. Science. 2002;297:1330–3.

    Article  CAS  PubMed  Google Scholar 

  11. Ferguson KM, Berger MB, Mendrola JM, Cho H-S, Leahy DJ, Lemmon MA. EGF activates Its receptor by removing interactions that autoinhibit ectodomain dimerization. Mol Cell. 2003;11:507–17.

    Article  CAS  PubMed  Google Scholar 

  12. Zhang X, Gureasko J, Shen K, Cole PA, Kuriyan J. An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell. 2006;125:1137–49.

    Article  CAS  PubMed  Google Scholar 

  13. Bose R, Zhang X. The ErbB kinase domain: structural perspectives into kinase activation and inhibition. Exp Cell Res. 2009;315:649–58.

    Article  CAS  PubMed  Google Scholar 

  14. Gaborit N, Lindzen M, Yarden Y. Emerging anti-cancer antibodies and combination therapies targeting HER3/ERBB3. Hum Vaccines Immunother. 2016;12:576–92.

    Article  Google Scholar 

  15. Baselga J, Swain SM. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer. 2009;9:463–75.

    Article  CAS  PubMed  Google Scholar 

  16. Wang Z. ErbB receptors and cancer. In: Wang Z, editor. ErbB receptor signaling. New York, NY: Springer; 2017. p. 3–35. http://link.springer.com/10.1007/978-1-4939-7219-7_1

    Google Scholar 

  17. Sergina NV, Rausch M, Wang D, Blair J, Hann B, Shokat KM, et al. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature. 2007;445:437–41.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Garrett JT, Olivares MG, Rinehart C, Granja-Ingram ND, Sanchez V, Chakrabarty A, et al. Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase. Proc Natl Acad Sci USA. 2011;108:5021–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Brand TM, Hartmann S, Bhola NE, Li H, Zeng Y, O’Keefe RA, et al. Cross-talk signaling between HER3 and HPV16 E6 and E7 mediates resistance to PI3K inhibitors in head and neck cancer. Cancer Res. 2018;78:2383–95.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Hutcheson IR, Goddard L, Barrow D, McClelland RA, Francies HE, Knowlden JM, et al. Fulvestrant-induced expression of ErbB3 and ErbB4 receptors sensitizes oestrogen receptor-positive breast cancer cells to heregulin β1. Breast Cancer Res. 2011;13. http://breast-cancer-research.biomedcentral.com/articles/10.1186/bcr2848

  21. Gazdar AF. Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene. 2009;28(S1):S24–31.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Petrelli F, Tomasello G, Barni S, Lonati V, Passalacqua R, Ghidini M. Clinical and pathological characterization of HER2 mutations in human breast cancer: a systematic review of the literature. Breast Cancer Res Treat. 2017;166:339–49.

    Article  CAS  PubMed  Google Scholar 

  23. Jaiswal BS, Kljavin NM, Stawiski EW, Chan E, Parikh C, Durinck S, et al. Oncogenic ERBB3 mutations in human cancers. Cancer Cell. 2013;23:603–17.

    Article  CAS  PubMed  Google Scholar 

  24. Junttila TT, Akita RW, Parsons K, Fields C, Lewis Phillips GD, Friedman LS, et al. Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941. Cancer Cell. 2009;15:429–40.

    Article  CAS  PubMed  Google Scholar 

  25. Mishra R, Alanazi S, Yuan L, Solomon T, Thaker TM, Jura N, et al. Activating HER3 mutations in breast cancer. Oncotarget. 2018;9. http://www.oncotarget.com/fulltext/25576

  26. Prigent SA, Gullick WJ. Identification of c-erbB-3 binding sites for phosphatidylinositol 3′-kinase and SHC using an EGF receptor/c-erbB-3 chimera. EMBO J. 1994;13:2831–41.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Steinkamp MP, Low-Nam ST, Yang S, Lidke KA, Lidke DS, Wilson BS. erbB3 is an active tyrosine kinase capable of homo- and heterointeractions. Mol Cell Biol. 2014;34:965–77.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  28. Umelo I, Noeparast A, Chen G, Renard M, Geers C, Vansteenkiste J, et al. Identification of a novel HER3 activating mutation homologous to EGFR-L858R in lung cancer. Oncotarget. 2016;7. http://www.oncotarget.com/fulltext/6585

  29. Shigematsu H, Gazdar AF. Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. Int J Cancer. 2006;118:257–62.

    Article  CAS  PubMed  Google Scholar 

  30. Kumar A, Petri ET, Halmos B, Boggon TJ. Structure and clinical relevance of the epidermal growth factor receptor in human cancer. J Clin Oncol. 2008;26:1742–51.

    Article  CAS  PubMed  Google Scholar 

  31. Yun C-H, Boggon TJ, Li Y, Woo MS, Greulich H, Meyerson M, et al. Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell. 2007;11:217–27.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Li M, Liu F, Zhang F, Zhou W, Jiang X, Yang Y, et al. Genomic ERBB2/ERBB3 mutations promote PD-L1-mediated immune escape in gallbladder cancer: a whole-exome sequencing analysis. Gut. 2018; https://gut.bmj.com/content/early/2018/06/27/gutjnl-2018-316039

  33. Li M, Zhang Z, Li X, Ye J, Wu X, Tan Z, et al. Whole-exome and targeted gene sequencing of gallbladder carcinoma identifies recurrent mutations in the ErbB pathway. Nat Genet. 2014;46:872–6.

    Article  CAS  PubMed  Google Scholar 

  34. Forbes SA, Beare D, Boutselakis H, Bamford S, Bindal N, Tate J, et al. COSMIC: somatic cancer genetics at high-resolution. Nucleic Acids Res. 2017;45:D777–83.

    Article  CAS  PubMed  Google Scholar 

  35. Narkis G, Ofir R, Manor E, Landau D, Elbedour K, Birk OS. Lethal congenital contractural syndrome type 2 (LCCS2) is caused by a mutation in ERBB3 (Her3), a modulator of the phosphatidylinositol-3-kinase/Akt pathway. Am J Hum Genet. 2007;81:589–95.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Chae J, Park WS, Kim MJ, Jang SS, Hong D, Ryu J, et al. Genomic characterization of clonal evolution during oropharyngeal carcinogenesis driven by human papillomavirus 16. BMB Rep. 2018;51:584–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Chang MT, Asthana S, Gao SP, Lee BH, Chapman JS, Kandoth C, et al. Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. Nat Biotechnol. 2016;34:155–63.

    Article  CAS  PubMed  Google Scholar 

  38. Chang MT, Bhattarai TS, Schram AM, Bielski CM, Donoghue MTA, Jonsson P, et al. Accelerating discovery of functional mutant alleles in cancer. Cancer Discov. 2018;8:174–83.

    Article  CAS  PubMed  Google Scholar 

  39. Mishra R, Patel H, Alanazi S, Yuan L, Garrett JT. HER3 signaling and targeted therapy in cancer. Oncol Rev. 2018;12:355.

    PubMed  PubMed Central  Google Scholar 

  40. Braunstein EM, Li R, Sobreira N, Marosy B, Hetrick K, Doheny K, et al. A germline ERBB3 variant is a candidate for predisposition to erythroid MDS/erythroleukemia. Leukemia. 2016;30:2242–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci USA. 2002;99:12293–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:2443–54.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, et al. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015;348:124–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Skoulidis F, Byers LA, Diao L, Papadimitrakopoulou VA, Tong P, Izzo J, et al. Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities. Cancer Discov. 2015;5:860–77.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Jeong EG, Soung YH, Lee JW, Lee SH, Nam SW, Lee JY, et al. ERBB3 kinase domain mutations are rare in lung, breast and colon carcinomas. Int J Cancer. 2006;119:2986–7.

    Article  CAS  PubMed  Google Scholar 

  46. Greenman C, Stephens P, Smith R, Dalgliesh GL, Hunter C, Bignell G, et al. Patterns of somatic mutation in human cancer genomes. Nature. 2007;446:153–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Koboldt DC, Fulton RS, McLellan MD, Schmidt H, Kalicki-Veizer J, McMichael JF, et al. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490:61–70.

    Article  CAS  Google Scholar 

  48. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2:401–4.

    Article  PubMed  Google Scholar 

  49. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6:pl1–pl1.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  50. Schrock AB, Devoe CE, McWilliams R, Sun J, Aparicio T, Stephens PJ, et al. Genomic profiling of small-bowel adenocarcinoma. JAMA Oncol. 2017;3:1546.

    Article  PubMed  PubMed Central  Google Scholar 

  51. Hänninen UA, Katainen R, Tanskanen T, Plaketti R-M, Laine R, Hamberg J, et al. Exome-wide somatic mutation characterization of small bowel adenocarcinoma. PLoS Genet. 2018;14:e1007200.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  52. Cabel L, Aparicio T, Bieche I, Svrcek M, Zaanan A, Afchain P, et al. ERBB3 activating mutations in small bowel adenocarcinomas. JCO Precis Oncol. 2018;2:1–9.

    PubMed  Google Scholar 

  53. The AACR Project GENIE Consortium. AACR project GENIE: powering precision medicine through an international consortium. Cancer Discov. 2017;7:818–31.

    Article  PubMed Central  Google Scholar 

  54. Desmedt C, Zoppoli G, Gundem G, Pruneri G, Larsimont D, Fornili M, et al. Genomic characterization of primary invasive lobular breast cancer. J Clin Oncol. 2016;34:1872–81.

    Article  CAS  PubMed  Google Scholar 

  55. Deniziaut G, Tille JC, Bidard F-C, Vacher S, Schnitzler A, Chemlali W, et al. ERBB2 mutations associated with solid variant of high-grade invasive lobular breast carcinomas. Oncotarget. 2016;7:73337–46.

    Article  PubMed  PubMed Central  Google Scholar 

  56. Cancer Genome Atlas Research Network, Albert Einstein College of Medicine, Analytical Biological Services, Barretos Cancer Hospital, Baylor College of Medicine, Beckman Research Institute of City of Hope, et al. Integrated genomic and molecular characterization of cervical cancer. Nature. 2017;543:378–84.

    Article  CAS  Google Scholar 

  57. Milewska M, Cremona M, Morgan C, O’Shea J, Carr A, Velanki SH, et al. Development of a personalized therapeutic strategy for ERBB-gene-mutated cancers. Ther Adv Med Oncol. 2018;10:1758834017746040.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  58. Loree JM, Bailey AM, Johnson AM, Yu Y, Wu W, Bristow CA, et al. Molecular landscape of ERBB2/ERBB3 mutated colorectal cancer. J Natl Cancer Inst. 2018;110:1409–17.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  59. Ross JS, Fakih M, Ali SM, Elvin JA, Schrock AB, Suh J, et al. Targeting HER2 in colorectal cancer: the landscape of amplification and short variant mutations in ERBB2 and ERBB3. Cancer. 2018;124:1358–73.

    Article  CAS  PubMed  Google Scholar 

  60. The Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012;487:330–7.

    Article  CAS  Google Scholar 

  61. Watson P, Riley B. The tumor spectrum in the lynch syndrome. Fam Cancer. 2005;4:245–8.

    Article  PubMed  Google Scholar 

  62. Connell CM, Doherty GJ. Activating HER2 mutations as emerging targets in multiple solid cancers. ESMO Open. 2017;2:e000279.

    Article  PubMed  PubMed Central  Google Scholar 

  63. Wang SE, Narasanna A, Perez-Torres M, Xiang B, Wu FY, Yang S, et al. HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. Cancer Cell. 2006;10:25–38.

    Article  PubMed  CAS  Google Scholar 

  64. Agus DB, Akita RW, Fox WD, Lewis GD, Higgins B, Pisacane PI, et al. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell. 2002;2:127–37.

    Article  CAS  PubMed  Google Scholar 

  65. Hyman DM, Piha-Paul SA, Won H, Rodon J, Saura C, Shapiro GI, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature. 2018;554:189–94.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  66. Burstein HJ, Sun Y, Dirix LY, Jiang Z, Paridaens R, Tan AR, et al. Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer. J Clin Oncol. 2010;28:1301–7.

    Article  CAS  PubMed  Google Scholar 

  67. Bidard F-C, Ng CKY, Cottu P, Piscuoglio S, Escalup L, Sakr RA, et al. Response to dual HER2 blockade in a patient with HER3-mutant metastatic breast cancer. Ann Oncol. 2015;26:1704–9.

    Article  PubMed  Google Scholar 

  68. Choudhury NJ, Campanile A, Antic T, Yap KL, Fitzpatrick CA, Wade JL, et al. Afatinib activity in platinum-refractory metastatic urothelial carcinoma in patients with ERBB alterations. J Clin Oncol. 2016;34:2165–71.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  69. Tamura S, Wang Y, Veeneman B, Hovelson D, Bankhead A, Broses LJ, et al. Molecular correlates of in vitro responses to dacomitinib and afatinib in bladder cancer. Bladder Cancer. 2018;4:77–90.

    Article  PubMed  PubMed Central  Google Scholar 

  70. Strickley JD, Spalding AC, Haeberle MT, Brown T, Stevens DA, Jung J. Metastatic squamous cell carcinoma of the skin with clinical response to lapatinib. Exp Hematol Oncol. 2018;7. https://ehoonline.biomedcentral.com/articles/10.1186/s40164-018-0111-z

  71. Chiou VL, Burotto M. Pseudoprogression and immune-related response in solid tumors. J Clin Oncol. 2015;33:3541–3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  72. Migden MR, Rischin D, Schmults CD, Guminski A, Hauschild A, Lewis KD, et al. PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma. N Engl J Med. 2018;379:341–51.

    Article  CAS  PubMed  Google Scholar 

  73. Verlingue L, Hollebecque A, Lacroix L, Postel-Vinay S, Varga A, El Dakdouki Y, et al. Human epidermal receptor family inhibitors in patients with ERBB3 mutated cancers: entering the back door. Eur J Cancer Oxf Engl. 2018;92:1–10.

    Article  CAS  Google Scholar 

  74. Douillard J-Y, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M, et al. Panitumumab–FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med. 2013;369:1023–34.

    Article  CAS  PubMed  Google Scholar 

  75. Chandarlapaty S, Sawai A, Scaltriti M, Rodrik-Outmezguine V, Grbovic-Huezo O, Serra V, et al. AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell. 2011;19:58–71.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  76. Narayan M, Wilken JA, Harris LN, Baron AT, Kimbler KD, Maihle NJ. Trastuzumab-induced HER reprogramming in “resistant” breast carcinoma cells. Cancer Res. 2009;69:2191–4.

    Article  CAS  PubMed  Google Scholar 

  77. Kennedy SP, Hastings JF, Han JZR, Croucher DR. The under-appreciated promiscuity of the epidermal growth factor receptor family. Front Cell Dev Biol. 2016;4. http://journal.frontiersin.org/Article/10.3389/fcell.2016.00088/abstract

  78. Frazier NM, Brand T, Gordan JD, Grandis J, Jura N. Overexpression-mediated activation of MET in the Golgi promotes HER3/ERBB3 phosphorylation. Oncogene. 2019;38:1936–50.

    Article  CAS  PubMed  Google Scholar 

  79. Zhang N, Chang Y, Rios A, An Z. HER3/ErbB3, an emerging cancer therapeutic target. Acta Biochim Biophys Sin. 2015;48:39–48.

    CAS  PubMed  Google Scholar 

  80. Zehir A, Benayed R, Shah RH, Syed A, Middha S, Kim HR, et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat Med. 2017;23:703–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  81. Hoadley KA, Yau C, Hinoue T, Wolf DM, Lazar AJ, Drill E, et al. Cell-of-origin patterns dominate the molecular classification of 10,000 tumors from 33 types of cancer. Cell. 2018;173:291–304.e6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Author notes

  1. These authors contributed equally: Nicolas Kiavue, Luc Cabel

Authors and Affiliations

  1. Department of Medical Oncology, Institut Curie, PSL Research University, Paris, France

    Nicolas Kiavue, Luc Cabel, Samia Melaabi, Guillaume Bataillon, Celine Callens, Florence Lerebours, Jean-Yves Pierga & Francois-Clement Bidard

  2. Versailles Saint Quentin en Yvelines University, Paris Saclay University, Saint Cloud, Paris, France

    Luc Cabel & Francois-Clement Bidard

  3. Paris Descartes University, Paris, France

    Jean-Yves Pierga

Authors
  1. Nicolas Kiavue
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Luc Cabel
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Samia Melaabi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Guillaume Bataillon
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Celine Callens
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Florence Lerebours
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Jean-Yves Pierga
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Francois-Clement Bidard
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Francois-Clement Bidard.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kiavue, N., Cabel, L., Melaabi, S. et al. ERBB3 mutations in cancer: biological aspects, prevalence and therapeutics. Oncogene 39, 487–502 (2020). https://doi.org/10.1038/s41388-019-1001-5

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41388-019-1001-5

This article is cited by

Search

Advanced search

Quick links